Why am I getting weird tingling or burning skin on retatrutide?
That symptom is called dysesthesia - an abnormal or unpleasant sense of touch, like pins-and-needles, prickling, or burning, usually in the hands, feet, or face. In the Phase 3 TRIUMPH-4 trial of retatrutide, dysesthesia was reported more often than with placebo, though most cases were mild and few participants stopped because of it. The likely cause is glucagon-receptor activity affecting peripheral nerves. Retatrutide is investigational and not approved; any decision about it belongs with a licensed provider.
- TRIUMPH-4 Phase 3 (Eli Lilly, December 2025): dysesthesia in trials a notable share; in trials a notable share; placebo a notable share
- Most cases mild; about a notable share discontinued specifically for dysesthesia
- Typical onset: dose escalation (weeks 4 to 16), some cases later
- Some resolved by week 40 to 50; long-term resolution data still limited
- Phase 2 TRIUMPH: dysesthesia was NOT reported - this signal emerged with longer Phase 3 follow-up
- Presentation: tingling, burning, prickling; hands, feet, or face most commonly; altered temperature sensation in some cases
Your guided peptide companion.
PRTCL walks beginners through their first peptide with confidence - guided reconstitution, syringe unit math from your own numbers, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.
- · Guided walkthrough for your first dose
- · Your vial and your dose, converted into syringe units
- · Vial inventory and dose log tracking
- · A library where every claim cites its source
Free to start.
%20-%20white.png)